YAP/TAZ是TGF-β2介导结膜纤维化的关键分子
该研究在人原代结膜成纤维细胞中探讨YAP/TAZ在TGF-β2介导结膜纤维化中的作用。TGF-β2稳定YAP/TAZ并激活Smad2/3,促进纤维化基因转录,YAP/TAZ抑制剂verteporfin可显著抑制纤维化改变。提示抑制YAP/TAZ可能改善青光眼滤过手术预后。
要点
- TGF-β2通过稳定YAP/TAZ激活Smad2/3,诱导结膜成纤维细胞纤维化基因转录。
- α-SMA、纤连蛋白、I型和IV型胶原主要由YAP调控,CTGF和CYR61依赖YAP和TAZ。
- YAP/TAZ抑制剂verteporfin可显著抑制TGF-β2介导的结膜成纤维细胞纤维化改变。
核心结论
- YAP/TAZ是结膜纤维化细胞模型中TGF-β2信号的核心枢纽,抑制YAP/TAZ可能改善青光眼滤过手术预后。
研究设计与样本
- 研究采用人原代结膜成纤维细胞,给予TGF-β2处理,通过Western blot和免疫细胞化学检测YAP/TAZ表达,并通过敲低实验和YAP/TAZ抑制剂verteporfin观察对纤维化改变的影响。
主要发现
- TGF-β2稳定YAP/TAZ并激活Smad2/3,促进人原代结膜成纤维细胞中纤维化基因转录。
- α-平滑肌肌动蛋白、纤连蛋白、I型胶原和IV型胶原主要受YAP调控,CCN家族蛋白CTGF和CYR61依赖YAP和TAZ。
- YAP/TAZ与Smad2/3空间位置接近,且YAP是TGF-β2介导Smad2/3磷酸化和核转位所必需。
- YAP/TAZ抑制剂verteporfin显著抑制TGF-β2介导的结膜成纤维细胞纤维化改变。
临床怎么用
- 在青光眼滤过手术相关的结膜纤维化中,YAP/TAZ可作为潜在抗纤维化干预靶点。
- verteporfin作为YAP/TAZ抑制剂在细胞模型中显示出抗纤维化效果,但尚未提供临床用药方案或剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the roles of Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ), the major effector molecules of the Hippo pathway, in TGF-β2-mediated conjunctival fibrosis. METHODS: Primary human conjunctival fibroblasts were treated with TGF-β2. The expression of YAP/TAZ was examined by Western blot analyses and immunocytochemistry. The expression of fibrotic proteins and genes were evaluated by Western blot analyses and quantitative real-time PCR, respectively. The effects of YAP/TAZ on fibrotic changes were examined by knockdown experiments and the YAP/TAZ inhibitor, verteporfin. RESULTS: TGF-β2 stabilized YAP/TAZ and subsequently activated Smad2/3, which led to the transcription of fibrotic genes in human primary conjunctival fibroblasts. These fibrotic genes were differently regulated by YAP/TAZ. Notably, α-smooth muscle actin, fibronectin, collagen I, and collagen IV were primarily regulated by YAP. In contrast, CCN family proteins (CTGF and CYR61) depended on both YAP and TAZ. Mechanistically, YAP/TAZ were located in close proximity to Smad2/3, and in particular, YAP was required for TGF-β2-mediated phosphorylation and the nuclear translocation of Smad2/3. Furthermore, a YAP/TAZ inhibitor markedly suppressed TGF-β2-mediated fibrotic changes in conjunctival fibroblasts. CONCLUSIONS: YAP/TAZ acted as a molecular hub of TGF-β2 signaling in a cellular model of conjunctival fibrosis. Moreover, verteporfin, a YAP/TAZ inhibitor exerted potent antifibrosis effects by suppressing TGF-β2-YAP/TAZ-Smad signaling. Our study highlights YAP/TAZ as essential regulators of conjunctival fibrosis and shows that inhibition of YAP/TAZ might potentially improve the outcomes of glaucoma filtration surgery.
引用
- Futakuchi A, Inoue T, Wei FY, et al. YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis. Invest Ophthalmol Vis Sci. 2018. PMID: 30025139. doi:10.1167/iovs.18-24258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。